• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

《在癌症项目中实施免疫检查点抑制剂的指南:来自加拿大大型社区中心的经验》。

A Guide to Implementing Immune Checkpoint Inhibitors within a Cancer Program: Experience from a Large Canadian Community Centre.

机构信息

Medical Oncology/Hematology, William Osler Health System, Brampton, ON L6R 3J7, Canada.

Department of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada.

出版信息

Curr Oncol. 2022 Feb 4;29(2):869-880. doi: 10.3390/curroncol29020074.

DOI:10.3390/curroncol29020074
PMID:35200573
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8870472/
Abstract

The increased use of immune checkpoint inhibitors across cancer programs has created the need for standardized patient assessment, education, monitoring, and management of immune-related adverse events (irAEs). At William Osler Health System in Brampton, Ontario, a practical step-wise approach detailing the implementation of cancer immunotherapy in routine practice was developed. The approach focuses on four key steps: (1) identification of patient educators; (2) development of patient education materials; (3) development of patient monitoring tools; (4) involvement and education of multidisciplinary teams. Here, we provide an in-depth description of what was included in each step and how we integrated the different elements of the program. For each step, resources, tools, and materials that may be useful for patients, healthcare providers, and multidisciplinary teams were developed or modified based on existing materials. At our centre, the program led to improved patient comprehension of irAEs, the ability to act on symptoms (patient self-efficacy), and low rates of emergency room visits at first presentation for irAEs. We recognize that centres may need to tailor the approaches to their institutional policies and encourage centres to adapt and modify the forms and tools according to their needs and requirements.

摘要

随着免疫检查点抑制剂在癌症治疗中的广泛应用,需要对免疫相关不良反应(irAEs)进行标准化的患者评估、教育、监测和管理。在安大略省宾顿的威廉·奥瑟尔健康系统(William Osler Health System),我们制定了一种实用的逐步方法,详细介绍了癌症免疫疗法在常规实践中的实施。该方法侧重于四个关键步骤:(1)确定患者教育者;(2)开发患者教育材料;(3)开发患者监测工具;(4)多学科团队的参与和教育。在这里,我们深入描述了每个步骤中包含的内容,以及我们如何整合该计划的不同要素。对于每个步骤,我们都根据现有材料开发或修改了针对患者、医疗保健提供者和多学科团队可能有用的资源、工具和材料。在我们中心,该计划提高了患者对 irAEs 的理解、对症状采取行动的能力(患者自我效能),并且 irAEs 首次就诊时急诊就诊的比例较低。我们认识到,各个中心可能需要根据自己的机构政策来调整这些方法,并鼓励中心根据自己的需求和要求来改编和修改表格和工具。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f941/8870472/242c74110b9e/curroncol-29-00074-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f941/8870472/87b175498a4d/curroncol-29-00074-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f941/8870472/2f8cef888ade/curroncol-29-00074-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f941/8870472/242c74110b9e/curroncol-29-00074-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f941/8870472/87b175498a4d/curroncol-29-00074-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f941/8870472/2f8cef888ade/curroncol-29-00074-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f941/8870472/242c74110b9e/curroncol-29-00074-g003.jpg

相似文献

1
A Guide to Implementing Immune Checkpoint Inhibitors within a Cancer Program: Experience from a Large Canadian Community Centre.《在癌症项目中实施免疫检查点抑制剂的指南:来自加拿大大型社区中心的经验》。
Curr Oncol. 2022 Feb 4;29(2):869-880. doi: 10.3390/curroncol29020074.
2
Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.癌症患者接受免疫检查点抑制剂治疗的特定免疫相关不良事件的真实世界临床和经济结局。
Oncologist. 2021 Nov;26(11):e2002-e2012. doi: 10.1002/onco.13918. Epub 2021 Aug 24.
3
The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.与免疫检查点抑制剂相关的极重度免疫相关不良事件的决定因素:法国 REISAMIC 注册前瞻性研究。
Eur J Cancer. 2021 Nov;158:217-224. doi: 10.1016/j.ejca.2021.08.048. Epub 2021 Oct 7.
4
Oral manifestations of immune-related adverse events in cancer patients treated with immune checkpoint inhibitors.免疫检查点抑制剂治疗的癌症患者的免疫相关不良事件的口腔表现。
Oral Dis. 2022 Jan;28(1):9-22. doi: 10.1111/odi.13964. Epub 2021 Aug 3.
5
Optimizing Care for Patients With Adverse Events From Immunotherapeutics.优化免疫治疗不良事件患者的护理。
Cancer J. 2020 Nov/Dec;26(6):537-542. doi: 10.1097/PPO.0000000000000492.
6
Diagnosis, monitoring, and management of adverse events from immune checkpoint inhibitor therapy.免疫检查点抑制剂治疗相关不良事件的诊断、监测和管理。
Curr Oncol. 2020 Apr;27(Suppl 2):S43-S50. doi: 10.3747/co.27.5111. Epub 2020 Apr 1.
7
Advances on immune-related adverse events associated with immune checkpoint inhibitors.免疫检查点抑制剂相关免疫相关不良事件的研究进展
Front Med. 2021 Feb;15(1):33-42. doi: 10.1007/s11684-019-0735-3. Epub 2020 Aug 10.
8
Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy.免疫相关不良事件与免疫检查点抑制剂在有食品和药物管理局批准的免疫治疗适应证的胃肠道癌患者中的疗效。
Oncologist. 2020 Aug;25(8):669-679. doi: 10.1634/theoncologist.2019-0637. Epub 2020 Jan 14.
9
Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management.与免疫检查点抑制剂相关的内分泌相关不良事件:管理的建议算法。
Oncologist. 2020 Apr;25(4):290-300. doi: 10.1634/theoncologist.2018-0470. Epub 2019 Oct 10.
10
[Predictive Biomarkers of Immune-related Adverse Events Induced by Checkpoint Inhibitors in Malignancies].[恶性肿瘤中检查点抑制剂诱导的免疫相关不良事件的预测生物标志物]
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2020 Dec 30;42(6):825-830. doi: 10.3881/j.issn.1000-503X.11534.

引用本文的文献

1
Immune-mediated enterocolitis is associated with immune checkpoint inhibitors: A pharmacovigilance study from the FDA Adverse Event Reporting System (FAERS) database.免疫介导的小肠结肠炎与免疫检查点抑制剂相关:一项来自美国食品药品监督管理局不良事件报告系统(FAERS)数据库的药物警戒研究。
PLoS One. 2025 Jun 4;20(6):e0325760. doi: 10.1371/journal.pone.0325760. eCollection 2025.
2
Patient and Caregiver Education to Support Self-Efficacy and Self-Management During Immunotherapy-An Integrative Review.支持免疫治疗期间自我效能和自我管理的患者及护理人员教育——一项综合综述
Psychooncology. 2025 Mar;34(3):e70100. doi: 10.1002/pon.70100.
3

本文引用的文献

1
Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review.自身免疫、检查点抑制剂治疗和免疫相关不良事件:综述。
Semin Cancer Biol. 2020 Aug;64:93-101. doi: 10.1016/j.semcancer.2019.06.012. Epub 2019 Jul 19.
2
Managing Immuno-Oncology Toxicity: Top 10 Innovative Institutional Solutions.管理免疫肿瘤学毒性:十大创新性机构解决方案。
Am Soc Clin Oncol Educ Book. 2019 Jan;39:96-104. doi: 10.1200/EDBK_100018. Epub 2019 May 17.
3
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Development of an eHealth-enhanced model of care for the monitoring and management of immune-related adverse events in patients treated with immune checkpoint inhibitors.
开发一种电子健康增强型护理模式,用于监测和管理接受免疫检查点抑制剂治疗的患者的免疫相关不良反应。
Support Care Cancer. 2023 Jul 22;31(8):484. doi: 10.1007/s00520-023-07934-w.
4
Risk of diabetes mellitus among users of immune checkpoint inhibitors: A population-based cohort study.免疫检查点抑制剂使用者发生糖尿病的风险:一项基于人群的队列研究。
Cancer Med. 2023 Apr;12(7):8144-8153. doi: 10.1002/cam4.5616. Epub 2023 Jan 16.
免疫检查点抑制剂相关致命性毒性作用:系统评价和荟萃分析。
JAMA Oncol. 2018 Dec 1;4(12):1721-1728. doi: 10.1001/jamaoncol.2018.3923.
4
New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity.NCCN 指南更新:免疫治疗相关毒性的识别与管理。
J Natl Compr Canc Netw. 2018 May;16(5S):594-596. doi: 10.6004/jnccn.2018.0047.
5
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary.接受免疫检查点抑制剂治疗患者免疫相关不良事件的管理:美国临床肿瘤学会临床实践指南摘要
J Oncol Pract. 2018 Apr;14(4):247-249. doi: 10.1200/JOP.18.00005. Epub 2018 Mar 8.
6
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.免疫检查点抑制剂治疗患者免疫相关不良反应的管理:美国临床肿瘤学会临床实践指南。
J Clin Oncol. 2018 Jun 10;36(17):1714-1768. doi: 10.1200/JCO.2017.77.6385. Epub 2018 Feb 14.
7
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade.与免疫检查点阻断相关的免疫相关不良事件。
N Engl J Med. 2018 Jan 11;378(2):158-168. doi: 10.1056/NEJMra1703481.
8
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.管理免疫检查点抑制剂相关毒性:癌症免疫治疗学会(SITC)毒性管理工作组的共识建议。
J Immunother Cancer. 2017 Nov 21;5(1):95. doi: 10.1186/s40425-017-0300-z.
9
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.纳武利尤单抗联合伊匹木单抗治疗晚期黑色素瘤的总生存期
N Engl J Med. 2017 Oct 5;377(14):1345-1356. doi: 10.1056/NEJMoa1709684. Epub 2017 Sep 11.
10
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.免疫疗法毒性管理:ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2017 Jul 1;28(suppl_4):iv119-iv142. doi: 10.1093/annonc/mdx225.